What Is TACT 1 AND TACT 2? EDTA CHELATIONNovember 15, 2017
At the Magaziner Center for Wellness, we are one of the leading centers specializing in EDTA chelation for people with cardiovascular problems (including past heart attacks) and for patients who cannot choose not to, undergo cardiac surgical procedures.
If you are looking for a good explanation about the link between chelation therapy and cardiovascular problems, the doctors at the Columbia University Division of Cardiology, at Mount Sinai Medical Center in Miami Beach, provide a good introduction to chelation therapy in their paper published in the journal: Trends in Cardiovascular Medicine.
“Medical practitioners have treated atherosclerotic disease (the buildup of plaque in arteries) with chelation therapy for some 60 years. Lack of strong evidence led conventional practitioners to abandon its use in the 1960s and 1970s. This relegated chelation therapy to complementary and alternative medicine practitioners, who reported good anecdotal results.”1
What is Chelation?
Chelation involves the intravenous infusion of vitamins, magnesium and a chelating agent known as EDTA.
This mixture serves to chelate, or bind, toxic heavy metals, calcium and free radicals in the blood vessel walls, which are then excreted in the urine. As a result, blood vessels become more pliable and circulation improves, leading to the reduction or elimination of chest pain and other symptoms of vascular disease. Patients, who have completed a course of chelation therapy, often notice an improvement in their energy and well-being, and are often able to reduce or eliminate their need for medication.
As research to support the use of EDTA Chelation (as an alternative to angioplasty, surgery and cardiovascular drugs) continues, the treatment remains controversial.
In the August 2017 edition of the medical journal, Expert Review of Clinical Pharmacology, doctors from the University of Wisconsin reaffirmed the concerns of the medical community.
In this research, the Wisconsin researchers noted:
“The off-label use of chelation therapy (disodium edetate or EDTA) for prevention of cardiovascular disease is widespread, despite the lack of convincing evidence for efficacy or approval from the Food and Drug Administration.
After the publication of results from the National Institute of Health-sponsored Trial to Assess Chelation Therapy (TACT), a randomized controlled trial (RCT) in patients after myocardial infarction (MI), there is a renewed interest in clarifying the role of this treatment modality for patients with coronary artery disease.
Although encouraging results were reported in TACT, the evidence is insufficient to recommend the routine use of chelation therapy even in the post-myocardial infarction diabetic subgroup, which appeared to benefit. The ongoing TACT2 trial may clarify its use in post-myocardial infarction diabetic patients.”2
What is TACT and TACT2?
The Magaziner Center often conducts clinical research trials, which has led Dr. Magaziner to be selected as an investigator of the NIH-approved Trial to Assess Chelation Therapy (TACT).
The results of this landmark study were first published in 2013 in the Journal of the American Medical Association (JAMA).3
From that paper:
“TACT is the first randomized trial designed and powered to evaluate the effects of an EDTA-based chelation regimen on clinical outcomes in patients with coronary disease.
The trial randomized 1708 patients, administered over 55,000 double-blinded infusions, and accrued over 6200 patient-years of follow-up experience.”
The data showed that, amongst patients with a prior myocardial infarction, a chelation regimen of 40 infusions of disodium EDTA, ascorbate, B-vitamins, and other components resulted in a modest reduction in a composite outcome of cardiovascular events. The treatment effect persisted over the 5-year follow-up period without an evident reduction in effectiveness.
More findings from that study were published in 2016 in the medical journal: Expert Review of Cardiovascular Therapy. In that study, case reports and case series suggested that chelation reduced adverse cardiovascular events in a post-myocardial infarction (MI) population. Patients with diabetes demonstrated an even greater benefit with a 41% relative reduction in risk of a cardiac event. 4
From the Mount Sinai Medical Center of Florida:
The National Center for Complementary and Integrative Health (NCCIH) of the National Institutes of Health (NIH) has awarded $37M to Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to initiate the second Trial to Assess Chelation Therapy (TACT2). The trial is also co-funded by the National Heart, Lung and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Environmental Health Sciences.
This study will measure the effects of chelation therapy coupled with oral vitamins on patients with diabetes.
TACT2 follows up on the positive results of TACT, a NIH-sponsored multicenter, double-blind safety and efficacy study, which took place from 2002- 2012 and was conducted in 134 sites across the United States and Canada.
TACT demonstrated an 18% reduction in recurrent heart events by chelation in patients who already had sustained a heart attack. Recurrent heart events measured in the study were death, heart attack, stroke, heart bypass or stent, and hospitalization for angina (chest pains). In 633 diabetic patients, there was an even larger benefit with a 41% reduction in recurrent heart events and a 43% reduction in deaths. Based on these results, the Mount Sinai and Duke scientists who conducted the trial felt that a repeat study was important to carry out.
TACT2 will narrow its focus to the group with the greatest benefit in the original study – diabetic patients 50- years of age or older who have survived a prior heart attack.
Cardiovascular disease, diabetes, and toxic metals in the blood
Numerous studies have suggested that complications of diabetes mellitus and cardiovascular disease may be caused by chemical reactions that happen in and to excess sugar in the blood. These reactions are catalyzed, or facilitated, by these harmful metals.
Research published in the Journal of the American College of Cardiology confirms and suggests that accumulation of lead and cadmium, is an important risk factor for cardiovascular disease and that removal of these metals may lead to the identification of new, modifiable risk factors for atherosclerotic cardiovascular disease. They are removed from the body most effectively by edetate disodium (EDTA) 5.
TACT 2 Is Looking For Participants!
Are you a diabetic, over 50, who has suffered a heart attack? You may be eligible to participate in a study to assess the impact of chelation therapy, to reduce your future risk of heart attack, stroke or sudden death. To find out more about the FREE, nationwide study, contact us at 856-324-6033.
For more information please visit: http://www.drmagaziner.com/tact2/
1 Peguero JG, Arenas I, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.Trends Cardiovasc Med. 2014 Aug;24(6):232-40. doi: 10.1016/j.tcm.2014.06.002. Epub 2014 Jun 12.
2. Sultan S, Murarka S, Jahangir A, Mookadam F, Tajik AJ, Jahangir A. Chelation therapy in cardiovascular disease: an update. Expert Review of Clinical Pharmacology. 2017 Aug 3
3 TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107.
4 Lamas GA, Ergui I. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? Expert Rev Cardiovasc Ther. 2016 May 5:1-12. [Epub ahead of print]
5 Lamas GA, Navas-Acien A, Mark DB, Lee KL. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy. J Am Coll Cardiol. 2016;67(20):2411-2418. doi:10.1016/j.jacc.2016.02.066